Itamar Medical Ltd. | Balance Sheet

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
65,536.00
71,353.60
139,023.30
100,599.90
37,549.40
24,180.50
Total Accounts Receivable
8,042.30
13,958.60
16,035.00
19,170.10
20,225.80
25,499.60
Inventories
4,349.20
5,739.90
6,260.70
7,150.80
8,023.00
9,050.40
Other Current Assets
683.80
665.40
583.70
712.00
590.20
2,077.60
Total Current Assets
78,611.20
91,717.60
161,902.70
127,632.80
66,388.40
60,808.10
Net Property, Plant & Equipment
1,669.60
2,140.30
2,937.70
3,879.40
3,548.00
4,532.70
Total Investments and Advances
704.60
509.80
688.70
1,104.60
1,086.60
1,363.90
Long-Term Note Receivable
-
-
3,007.80
2,536.30
1,642.10
908
Intangible Assets
1,183.60
801.60
1,101.20
989.10
961.60
1,113.60
Other Assets
385.30
424.20
556.40
665.80
239.50
-
Total Assets
82,554.30
95,593.50
170,194.50
136,808.00
73,866.30
68,726.30
ST Debt & Current Portion LT Debt
24,984.30
-
-
37,027.90
37,132.80
Accounts Payable
2,443.60
4,214.40
4,105.10
5,095.60
4,381.20
Other Current Liabilities
12,197.10
14,122.10
13,871.60
12,989.20
13,223.50
Total Current Liabilities
39,624.90
18,336.50
17,976.70
55,112.70
54,737.50
Long-Term Debt
44,220.50
56,671.20
58,000.00
31,443.50
-
Provision for Risks & Charges
312.40
1,330.90
653.70
600.40
1,076.20
Other Liabilities
49,222.30
35,653.50
25,291.80
26,170.80
9,981.00
Total Liabilities
133,380.10
111,992.00
101,922.20
113,327.30
65,794.70
Common Equity (Total)
50,825.90
18,562.20
65,957.20
20,170.80
4,780.50
Total Shareholders' Equity
50,825.90
18,562.20
65,957.20
20,170.80
4,780.50
Total Equity
50,825.90
18,562.20
65,957.20
20,170.80
4,780.50
Liabilities & Shareholders' Equity
82,554.30
95,593.50
170,194.50
136,808.00
73,866.30
Non-Equity Reserves
-
2,163.60
2,315.20
3,309.80
3,291.10

About Itamar Medical

View Profile
Address
9 Halamish Street
Caesarea HA 38900
Israel
Employees -
Website http://www.itamar-medical.com
Updated 07/08/2019
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. The firm develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease.